[The role of betaserk in combined treatment of neurosensory hypoacusis and vestibulopathy in childhood].
Betaserk treatment was given to 78 children aged 6 to 14 years suffering from acute or progressive neurosensory hypoacusis (n=62) and vestibulopathy (n=16). The best results were achieved in vestibulopathy in older children. Stable improvement of hearing in the range 10--20 dB was achieved in 16 (30.7%) children, stable hearing stabilization was seen in 32 (61.4%) cases. Betaserk was well tolerated, had no side effects. Thus, betaserk is effective in the treatment of children with vestibulopathy, acute and progressive neurosensory hypoacusis.
Chistiakova
V R
VR
D000208:Acute Disease; D000293:Adolescent; D001621:Betahistine / Q000627:therapeutic use*; D002648:Child; D006309:Hearing / Q000187:drug effects; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D017442:Histamine Agonists / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome; D015837:Vestibular Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy
D017442:Histamine Agonists; D001621:Betahistine